Revenue Breakdown
Composition ()
No data
Revenue Streams
Embecta Corp (EMBC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pen Needles, accounting for 71.1% of total sales, equivalent to $187.80M. Other significant revenue streams include Safety and Syringes. Understanding this composition is critical for investors evaluating how EMBC navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Embecta Corp maintains a gross margin of 62.19%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 32.69%, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively EMBC converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, EMBC competes directly with industry leaders such as AVNS and CTKB. With a market capitalization of $603.96M, it holds a significant position in the sector. When comparing efficiency, EMBC's gross margin of 62.19% stands against AVNS's 48.37% and CTKB's 52.69%. Such benchmarking helps identify whether Embecta Corp is trading at a premium or discount relative to its financial performance.
